Brief: Jacobio Pharmaceuticals Says Received IND Approval For GUE Inhibitor JAB-24114
17/03/2023 13:49
March 17 (Reuters) - Jacobio Pharmaceuticals Group Co
Ltd 1167.HK :
* RECEIVED IND APPROVAL FOR GUE INHIBITOR JAB-24114 FROM
CENTER
FOR DRUG EVALUATION OF CHINA NMPA
Source text for Eikon: ID:nHKS1rQ7Xq
Further company coverage: 1167.HK
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan